Last reviewed · How we verify
NCT02916472
CyberCycling to Reduce Therapeutic Side Effects and Improve Quality of Life in AYA Cancers
NA trial testing CyberCycling in Adolescent and Young Adult Cancers in 9 participants. Completed in 23 February 2024.
30 June 2023
Quick facts
| Lead sponsor | Case Comprehensive Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 9 |
| Start date | 24 August 2016 |
| Primary completion | 30 June 2023 |
| Estimated completion | 23 February 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CyberCycling
- Stretching
- Resistance Bands
Conditions studied
- Adolescent and Young Adult Cancers — all drugs for Adolescent and Young Adult Cancers →
Sponsor
Case Comprehensive Cancer Center — full company profile →
Who can join
Adults 15 to 30, any sex, with Adolescent and Young Adult Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Only a few clinical trials evaluating the potential benefits of exercise have been conducted in adolescents and young adults (AYA) with cancer and, no prior studies have evaluated the potential effects of 'cybercycling' (exergaming on a stationary bike) in AYA cancer survivors. Therefore, the study aims to conduct a pilot trial to determine feasibility (adherence, user acceptance) and to explore potential effects of a 'cybercycling' exercise program on fitness, body composition, quality of life, sleep and cognition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02916472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Case Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
- NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
- NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
- NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
- NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02916472 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
- Last refreshed: 1 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02916472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing